细胞因子诱导的杀伤细胞对人肺癌的抗肿瘤活性。

Antitumor activity of cytokine-induced killer cells against human lung cancer.

作者信息

Kim Hwan Mook, Lim Jaeseung, Park Song-Kyu, Kang Jong Soon, Lee Kiho, Lee Chang Woo, Lee Ki Hoon, Yun Mi-Jung, Yang Kyu-Hwan, Han Gyoonhee, Kwon Soon Woo, Kim Youngsoo, Han Sang-Bae

机构信息

Bioevaluation center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Chungbuk 363-883, South Korea.

出版信息

Int Immunopharmacol. 2007 Dec 15;7(13):1802-7. doi: 10.1016/j.intimp.2007.08.016. Epub 2007 Sep 7.

DOI:10.1016/j.intimp.2007.08.016

PMID:17996691

Abstract

Lung cancer is the leading cause of cancer-related death among men and women in the world. Despite the aggressive treatment with surgery, radiation and chemotherapy, the long term survival for lung cancer patients remains low. In this study, the anti-tumor activity of cytokine-induced killer (CIK) cells against human lung cancer was evaluated in vitro and in vivo. Although CD3(+)CD56(+) CIK cells were rare in fresh human peripheral blood mononuclear cells, they could expand more than 1000-fold on day 14 in the presence of anti-CD3 antibody plus IL-2. At an effector-target cell ratio of 30:1, CIK cells destroyed 98% of NCI-H460 human lung cancer cells, which was determined by the (51)Cr-release assay. In addition, CIK cells at doses of 3 and 30 million cells per mouse inhibited 57% and 77% of NCI-H460 tumor growth in nude mouse xenograft assay, respectively. This study suggests that CD3(+)CD56(+) CIK cells may be used as an adoptive immunotherapy for patients with lung cancer.

摘要

肺癌是全球男性和女性癌症相关死亡的主要原因。尽管采用了手术、放疗和化疗等积极的治疗方法，但肺癌患者的长期生存率仍然很低。在本研究中，在体外和体内评估了细胞因子诱导的杀伤（CIK）细胞对人肺癌的抗肿瘤活性。虽然新鲜人外周血单个核细胞中CD3(+)CD56(+) CIK细胞很少见，但在抗CD3抗体加IL-2存在的情况下，它们在第14天可扩增1000倍以上。在效应细胞与靶细胞比例为30:1时，CIK细胞破坏了98%的NCI-H460人肺癌细胞，这是通过(51)Cr释放试验确定的。此外，在裸鼠异种移植试验中，每只小鼠注射300万和3000万个CIK细胞的剂量分别抑制了57%和77%的NCI-H460肿瘤生长。本研究表明，CD3(+)CD56(+) CIK细胞可作为肺癌患者的过继性免疫疗法。